Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12418999 | 0.83 | MGLL (0.33) | KMT2AMEN1LMNAMGLL | |
| SCHEMBL8721919 | 0.82 | ALDH1A1 (0.33) | ALDH1A1KMT2AMEN1LMNARAB9A | |
| SCHEMBL9314823 | 0.82 | ALDH1A1 (0.33) | ALDH1A1KMT2AMEN1LMNARAB9A | |
| SCHEMBL14310541 | 0.82 | NAAA (0.37) | ALDH1A1KMT2ALMNARAB9A | |
| SCHEMBL28668764 | 0.81 | GSK3A (0.35) | ALDH1A1 | |
| SCHEMBL277826 | 0.80 | MGLL (0.33) | KMT2AMGLLATM | |
| SCHEMBL261924 | 0.79 | MGLL (0.35) | ALDH1A1KMT2AMEN1LMNARAB9A | |
| SCHEMBL16133577 | 0.79 | MGLL (0.35) | ALDH1A1KMT2AMEN1LMNARAB9A | |
| SCHEMBL14753540 | 0.79 | — | — | |
| SCHEMBL11955590 | 0.79 | TSHR (0.32) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207286-A1 | CONJUGATES OF A CHOLINESTERASE MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2018-07-26 | — | — | US | disclosed |
| US-20180085468-A1 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2018-03-29 | — | — | US | disclosed |
| US-9763995-B2 | Polymer conjugates of protegrin peptides | NEKTAR THERAPEUTICS (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2017-07-13 | — | — | US | disclosed |
| US-9636412-B2 | Conjugates of an anti-TNF-alpha antibody | NEKTAR THERAPEUTICS (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-20160158311-A1 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES | NEKTAR THERAPEUTICS | 2016-06-09 | — | — | US | disclosed |
| US-9347054-B2 | Polymer factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160030587-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2016-02-04 | — | — | US | disclosed |
| US-9101670-B2 | Conjugates of an anti-TNF-α antibody | NEKTAR THERAPEUTICS (US) | 2015-08-11 | — | — | US | disclosed |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | ALDH1A1 3597/4885KMT2A 1613/4885MEN1 3764/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | ALDH1A1 2770/4885KMT2A 1159/4885MEN1 865/4885 |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | ALDH1A1 3118/4885KMT2A 2002/4885MEN1 844/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | ALDH1A1 2876/4885KMT2A 2142/4885MEN1 778/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 2494/4885KMT2A 4160/4885MEN1 1777/4885 |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | ALDH1A1 2770/4885KMT2A 1159/4885MEN1 865/4885 |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 2449/4885KMT2A 4093/4885MEN1 1731/4885 |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | ALDH1A1 3118/4885KMT2A 2002/4885MEN1 844/4885 |
| US-20160030587-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 2494/4885KMT2A 4160/4885MEN1 1777/4885 |
| US-20160158311-A1 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES | PSMG3, PSMB11, UBQLN1 | ALDH1A1 4834/4885KMT2A 3816/4885MEN1 1753/4885 |
| US-20180085468-A1 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | IL2, IL2RA, ILF2 | ALDH1A1 3489/4885KMT2A 797/4885MEN1 3695/4885 |
| US-20180207286-A1 | CONJUGATES OF A CHOLINESTERASE MOIETY AND A POLYMER | BCHE, ACHE, DNPEP | ALDH1A1 817/4885KMT2A 896/4885MEN1 1284/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | ALDH1A1 2393/4885KMT2A 1218/4885MEN1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.